Pao Ling Biotechnology

Pao Ling Biotechnology is a Taiwan-based pharmaceutical and healthcare company primarily known for the development of Auryxia (ferric citrate), an FDA-approved phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in patients with chronic kidney disease (CKD). The company operates through several strategic business units, including pharmaceuticals, diagnostic medical devices, and medical aesthetics/functional skincare. Pao Ling maintains significant global reach through licensing partnerships with companies such as Akebia Therapeutics and Japan Tobacco for the commercialization of its renal products. Beyond nephrology, the company produces rapid diagnostic kits and a variety of cosmeceutical products under the Dr. Pro-Bioling brand. Listed on the Taiwan Stock Exchange, Pao Ling continues to expand its R&D efforts into dermatology and other specialty therapeutic areas.